The IPA has been informed that Spark Therapeutics has realigned its portfolio and made the difficult decision to stop its Pompe program. This includes the Phase 1/2 Investigational Gene Transfer Study, Resolute, for Adults with Late-Onset Pompe Disease (LOPD).
Letter to our community from Spark Therapeutics•0